Physics in Medicine and Biology | Year: 2010
We present a novel framework that enables very large scale intensity-modulated radiation therapy (IMRT) planning in limited computation resources with improvements in cost, plan quality and planning throughput. Current IMRT optimization uses a voxel-based beamlet superposition (VBS) framework that requires pre-calculation and storage of a large amount of beamlet data, resulting in large temporal and spatial complexity. We developed a non-voxelbased broad-beam (NVBB) framework for IMRT capable of direct treatment parameter optimization (DTPO). In this framework, both objective function and derivative are evaluated based on the continuous viewpoint, abandoning 'voxel' and 'beamlet' representations. Thus pre-calculation and storage of beamlets are no longer needed. The NVBB framework has linear complexities (O(N3)) in both space and time. The low memory, full computation and data parallelization nature of the framework render its efficient implementation on the graphic processing unit (GPU). We implemented the NVBB framework and incorporated it with the TomoTherapy treatment planning system (TPS). The new TPS runs on a single workstation with one GPU card (NVBB-GPU). Extensive verification/validation tests were performed in house and via third parties. Benchmarks on dose accuracy, plan quality and throughput were compared with the commercial TomoTherapy TPS that is based on the VBS framework and uses a computer cluster with 14 nodes (VBS-cluster). For all tests, the dose accuracy of these two TPSs is comparable (within 1%). Plan qualities were comparable with no clinically significant difference for most cases except that superior target uniformity was seen in the NVBBGPU for some cases. However, the planning time using the NVBB-GPU was reduced many folds over the VBS-cluster. In conclusion, we developed a novel NVBB framework for IMRT optimization. The continuous viewpoint and DTPO nature of the algorithm eliminate the need for beamlets and lead to better plan quality. The computation parallelization on a GPU instead of a computer cluster significantly reduces hardware and service costs. Compared with using the current VBS framework on a computer cluster, the planning time is significantly reduced using the NVBB framework on a single workstation with a GPU card. © 2010 Institute of Physics and Engineering in Medicine.
Ricardi U.,University of Turin |
Filippi A.R.,University of Turin |
Expert Review of Anticancer Therapy | Year: 2013
Stereotactic ablative radiotherapy (SABR) is a form of very precise radiotherapy that delivers high doses to tumors while sparing adjacent organs at risk. Recent data show that SABR is a low-toxic and highly effective local treatment for metastatic localizations in various organs, obtaining local control rates of approximately 80%. Experimental evidence also suggests that SABR may play an important therapeutic role in oligometastatic/oligorecurrent/ oligoprogressive patients, a subset of cancer patients who are probably in an intermediate disease state between localized disease and widespread dissemination. There is a strong biological and clinical rationale in combining the high local control rates achievable with SABR with effective systemic therapies, and recent results of pilot studies indicate that SABR may have a potential impact on prognosis in this subgroup of patients, being 'curative' in around 20-25% of cases. This paper reviews and discusses basic concepts and clinical applications of SABR in oligometastatic patients. © 2013 Informa UK, Ltd.
TomoTherapy | Date: 2013-01-11
A dose calculation tool operable to generate a variance map that represents a dose uncertainty. The variance map illustrates on a point-by-point basis where high uncertainty in the dose may exist and where low uncertainty in the dose may exist. The dose uncertainty is a result of an error in one or more data parameters related to a delivery parameter or a computational parameter.
TomoTherapy | Date: 2010-08-31
A patient support device of a radiation therapy treatment system includes an electromechanical motor and control system for moving the support device. The control system utilizes regenerative braking concepts, converting the motor into a generator as the support device is moved such that no matter the load, the support device will be moved at a constant speed. The control system also allows for moving of the support device in the powered off situation (i.e., when there is no power to the support device).
News Article | April 23, 2015
SUNNYVALE, California, April 23, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the company will highlight new CyberKnife® and TomoTherapy® technologies at the European Society for Therapeutic Radiology and Oncology (ESTRO) meeting, booth #2100, in Barcelona, Spain, April 24 – 27, 2015. The CyberKnife and TomoTherapy Systems are used to treat cancerous and benign tumors throughout the body. Each system precisely targets the tumor, delivering the prescribed radiation dose, while minimizing exposure to nearby healthy organs and tissues. At ESTRO, Accuray will showcase: For more information please visit Accuray website. The new Delivery Analysis Software for the TomoTherapy System Delivery Analysis for the TomoTherapy System recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), in conjunction with the CE Mark in the European Union. The Delivery Analysis software is an innovative tool that leverages the unique architecture of the TomoTherapy System to provide unprecedented access to treatment delivery information. The software provides enhanced confidence in system performance before each treatment, and actionable insights to help ensure all treatments stay on track. A pre-treatment test of the multileaf collimator (MLC) checks for differences between expected and measured MLC performance using pulse-by-pulse detector signals. Additionally, an in-treatment analysis of each delivered fraction is generated from exit detector data. It allows physicians to see if a particular fraction was not delivered as expected and helps to clarify the nature of the issue that led to the dose miss observed. An enhanced Synchrony® Respiratory Tracking System for the CyberKnife System The Synchrony System is the only clinically proven system that uses continual image guidance to automatically adjust the movement of the beam in synchronization with movement of the target volume. This new technology enables clinicians to: Satellite Symposium: "Radiation Therapy: Connecting History, Innovation and Patients" The symposium will be held on Saturday, 25 April 2015 from 13:15 to 14:30, room 111 (level 1). Presentations will explore the progress that has been made over the last 30 years in radiation therapy and discuss Accuray's contribution to setting the standard for the precise treatments that are used today and will be used in the future. Chaired by Prof. Jurgen Peter Debus, M.D., Ph.D., Managing Director of the Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, Symposium speakers will include: Dr. Cary Adams, CEO, the Union for International Cancer Control (UICC) and Chair of the NCD Alliance in Geneva, Switzerland; Prof. Ben J.M. Heijmen, Ph.D., Head of the Section of Medical Physics, Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, The Netherlands; and Prof. Thomas Rockwell Mackie, Ph.D., Emeritus Professor, Departments of Medical Physics and Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, USA. About Accuray Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in and future contributions to radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's reports on Form 10-Q, filed on November 7, 2014 and February 6, 2015, and the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.